VESTECK, Inc., an early-stage medical device company, recently announced its initial close on $4.3M of Series A financing, which includes conversion of all existing convertible notes. Funds will support the manufacturing of products, pre-clinical testing and completion of in human procedures, prior to the clinical study for FDA clearance.
VESTECK has designed a platform technology comprised of 6 devices that integrate the delivery of nitinol sutures into a catheter, improving clinical outcomes for endovascular aortic aneurysm patients.
Congratulations to Joseph W. Rafferty and the Vesteck team for a successful fund raise. Click here to read more.